Physician profile
Ryan Glen Smith
NPI 1639197452
$1,038.16
in general payments reported to CMS, 2019-2025
10 companies · $74.93 in 2025
The $74.93 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.84 · 2020: $22.12 · 2022: $222 · 2023: $61.36 · 2024: $568 · 2025: $74.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $505 · Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $504.97 |
| Food and Beverage | $199.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $532.01 | 2022-2024 | Linq II |
| Janssen Pharmaceuticals, INC | $169.34 | 2022-2024 | Xarelto |
| Bausch & Lomb Americas INC. | $63.10 | 2023-2024 | Envista Mx60 Iol, Amvisc |
| Medtronic Vascular, INC. | $52.20 | 2019-2020 | |
| Stryker Corporation | $46.29 | 2025 | N/A |
| Abbott Laboratories | $44.49 | 2022 | |
| Boston Scientific Corporation | $44.28 | 2019 | |
| Dompe US, INC. | $42.33 | 2023 | Oxervate |
| Novo Nordisk INC | $28.64 | 2025 | Wegovy |
| Ge Healthcare | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.